Younger CRC Screening; AI and Lung Cancer Detection; COVID and Oncology Trials thumbnail

Younger CRC Screening; AI and Lung Cancer Detection; COVID and Oncology Trials

Increasing colorectal cancer cases in people under 50 prompted the U.S. Preventive Services Task Force to recommend screening begin at age 45 for individuals at average risk. (JAMA)

Researchers developed an algorithm using artificial intelligence that can predict whether CT-detected lung nodules will turn cancerous. (Radiological Society of North America, Radiology)

Cancer centers are under fire for charging patients “exorbitant” parking fees. (NBC News)

The FDA accepted a biologics license application for sintilimab injection, in combination with pemetrexed (Alimta) and chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer, Innovent Biologics and Eli Lilly announced.

People with a high genetic risk for colon cancer can substantially reduce their risk — even more than those with a low genetic risk — by maintaining a healthy lifestyle. (Vanderbilt Medical Center, American Journal of Clinical Nutrition)

“Turning off” the CRTC3 protein could be a strategy for treating melanoma. (Salk Institute, Cell Reports)

While COVID-19 seriously disrupted oncology trials during the early stages of the pandemic, the impact has been less severe than in non-oncology trials. (Nature Reviews Drug Discovery)

Despite high mortality rates, few women in sub-Saharan Africa undergo screening for cervical cancer. (Penn State News, Cancer Epidemiology)

Inhibiting the Toll-like receptor 4 (TLR4) could be the key to preventing hearing loss in childhood cancer patients treated with cisplatin. (University of Alberta, EMBO Reports)

A drug originally developed to treat osteoporosis may be effective in therapy-resistant estrogen receptor-positive metastatic breast cancer. (Breast Cancer Research)

Petco is now offering a multi-cancer diagnostic test called OncoK9 for dogs at 30 of its full-service veterinary hospitals across the U.S. (San Diego Union-Tribune)

The FDA has granted BOLD-100, a first-in-class ruthenium-based small molecule therapeutic, an orphan drug designation for the treatment of gastric cancer, Bold Therapeutics announced.

How prevalent was cancer in the pre-industrialized world? (National Geographic, Cancer)

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *